Hey, does anyone remember that randomised, doubleblind trial with a couple of hundred Covid ARDS patients, where half of them got doses of Remestemcel to match the dosing used with GVHD?
Wonder if they had any assay data from that trial that they were able to share with FDA in relation to the GVHD application.
Just thinking out loud.
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-1007
-
- There are more pages in this discussion • 90 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
93.5¢ |
Change
0.020(2.19%) |
Mkt cap ! $1.067B | |||
| Open | High | Low | Value | Volume |
| 92.0¢ | 94.5¢ | 92.0¢ | $1.622M | 1.742M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 64563 | 93.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.0¢ | 204239 | 3 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |